Trial of Org10172 in Acute Stroke Treatment (TOAST) was the first large multi-center trial to be managed by the CTSDMC. The TOAST study began in 1989, and involved 42 participating clinical centers throughout the United States, and the Clinical Coordinating Center for that trial was located in the Department of Neurology at The University of Iowa. The CTSDMC partnered, at the time under the direction of of Dr. Robert "Skip" Woolson, partnered with Dr. Harold Adams in the Department of Neurology to run this placebo-controlled, double-blind, multi-center study examining the efficacy of a low molecular weight heparinoid agent (ORG10172) in the acute treatment of stroke patients. TOAST recruited 1,234 patients from 34 centers across the United States. The study employed a distributed data entry system, a novel approach at the time.